Low-dose sulbactam-durlobactam for recurrent CRAB pneumonia in a child with cerebral palsy: a Case Report from a resource-limited setting
Abstract
Background: Pediatric data for sulbactam-durlobactam (SUL-DUR) are extremely scarce, and no standard pediatric dosing exists.
Methods: We report a 6-year-old boy with cerebral palsy and epilepsy who developed recurrent ventilator-associated pneumonia caused by OXA-23-producing carbapenem-resistant Acinetobacter baumannii (CRAB).
Results: Due to financial constraints, a reduced-dose SUL-DUR regimen (150 mg/kg/day, q6h, 3-h infusion) was combined with cefoperazone-sulbactam to achieve a total sulbactam dose of 150 mg/kg/day. The patient defervesced within 48 h, inflammatory markers declined, chest imaging improved markedly, and he was transferred out of the PICU after 12 days of therapy.
Conclusion: A PK/PD-driven low-dose SUL-DUR strategy may represent a feasible and potential cost-saving strategy for pediatric CRAB pneumonia in resource-limited settings.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.